Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn’s patients: Results of the APPRECIA trial

In APPRECIA trial, Crohn's disease (CD) patients undergoing intestinal resection were randomized to postoperative adalimumab (ADA) or azathioprine (AZA). To evaluate health-related quality of life (HRQoL) in APPRECIA trial. HRQoL was evaluated using disease-specific shortened Spanish version of...

Full description

Saved in:
Bibliographic Details
Published in:Digestive and liver disease 2019-04, Vol.51 (4), p.529-535
Main Authors: Taxonera, Carlos, López-Sanromán, Antonio, Vera-Mendoza, Isabel, Domènech, Eugeni, Ruiz, Vicente Vega, Marín-Jiménez, Ignacio, Guardiola, Jordi, Castro, Luisa, Esteve, María, Iglesias, Eva, Ceballos, Daniel, Martínez-Montiel, Pilar, Gisbert, Javier P., Mínguez, Miguel, Echarri, Ana, Calvet, Xavier, Barrio, Jesús, Hinojosa, Joaquín, Martín-Arranz, María Dolores, Márquez-Mosquera, Lucía, Bermejo, Fernando, Rimola, Jordi, Alba, Cristina, Pons, Vicente, Nos, Pilar
Format: Article
Language:English
Subjects:
Adalimumab
Crohn’s disease
Postoperative recurrence
Postoperative therapy
Quality of life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In APPRECIA trial, Crohn's disease (CD) patients undergoing intestinal resection were randomized to postoperative adalimumab (ADA) or azathioprine (AZA). To evaluate health-related quality of life (HRQoL) in APPRECIA trial. HRQoL was evaluated using disease-specific shortened Spanish version of the IBDQ (SIBDQ-9) and generic European Quality of Life-5 Dimensions (EQ-5D) questionnaires, completed at baseline and at weeks 24 and 52. Sixty-one patients (37 ADA and 24 AZA) had evaluable data for HRQoL. Patients treated with ADA or AZA had significant improvement from baseline to weeks 24 and 52 in SIBDQ-9 and EQ-5D (p 
ISSN:1590-8658
1878-3562
DOI:10.1016/j.dld.2019.01.002